<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="More recent antibodies have been developed as subcutaneous injections, and" exact="adalimumab" post="has taken over as the market leader, with an"/>
 <result pre="Phase II clinical studies [15]—is 100 times more potent than" exact="palivizumab" post="in vitro. It is being developed as a single"/>
 <result pre="surface, escaping degradation [24, 25]. This approach was followed for" exact="bevacizumab" post="and cetuximab, by mutating Met428 to Leu and Asn434"/>
 <result pre="not possible or desirable. In the case of inhalational anthrax," exact="raxibacumab" post="has been approved using the FDA &quot;Animal Rule�? [33]."/>
 <result pre="to start to build one, with the recent characterization of" exact="praziquantel" post="for such use in murine models and in pediatrics."/>
 <result pre="consisting of a full treatment course of 3 days of" exact="amodiaquine" post="and 1 dose of sulfadoxine/pyrimethamine. It is given monthly"/>
 <result pre="67CoulibalyJT, PanicG, SilueKD, KovacJ, HattendorfJ, KeiserJ. Efficacy and safety of" exact="praziquantel" post="in preschool-aged and school-aged children infected with Schistosoma mansoni:"/>
 <result pre="VargasM, ReimersN, HaasH, SpangenbergT. Evaluation of the pharmacokinetic-pharmacodynamic relationship of" exact="praziquantel" post="in the Schistosoma mansoni mouse model. PLoS Negl Trop"/>
 <result pre="2017;11(9):e000594210.1371/journal.pntd.000594228934207 70BonatePL, WangT, PassierP, BagchusW, BurtH, LupfertC, et al.Extrapolation of" exact="praziquantel" post="pharmacokinetics to a pediatric population: a cautionary tale. Journal"/>
</results>
